KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Cash (2016 - 2025)

Arbutus Biopharma's Change in Cash history spans 13 years, with the latest figure at -$15.0 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 51.51% year-over-year to -$15.0 million; the TTM value through Sep 2025 reached -$9.4 million, down 165.93%, while the annual FY2024 figure was $10.0 million, 323.67% up from the prior year.
  • Change in Cash for Q3 2025 was -$15.0 million at Arbutus Biopharma, down from $336000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $46.9 million in Q3 2021 and bottomed at -$48.5 million in Q2 2021.
  • The 5-year median for Change in Cash is $746000.0 (2025), against an average of -$1.6 million.
  • The largest YoY upside for Change in Cash was 604.74% in 2021 against a maximum downside of 348.77% in 2021.
  • A 5-year view of Change in Cash shows it stood at $31.4 million in 2021, then crashed by 78.43% to $6.8 million in 2022, then rose by 29.27% to $8.8 million in 2023, then tumbled by 48.78% to $4.5 million in 2024, then plummeted by 434.61% to -$15.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Change in Cash are -$15.0 million (Q3 2025), $336000.0 (Q2 2025), and $746000.0 (Q1 2025).